Hormone Replacement Therapy Market Set to Grow at 6.48% CAGR Through 2030, Driven by Rising Demand
Hormone Replacement Therapy companies working in the market are Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F. Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.
(Albany, USA) DelveInsight's ' Hormone Replacement Therapy Market Insights, Competitive Landscape, and Market Forecast–2030 ' report provides a comprehensive analysis of the global hormone replacement therapy (HRT) market, focusing on adoption trends, technological advancements, and market dynamics across key regions. The report examines market growth, offering historical and projected market sizes, revenue trends, and key factors driving the demand for HRT in managing hormonal imbalances.
The report highlights the evolving landscape of hormone replacement therapies, exploring advancements in bioidentical hormones, transdermal delivery systems, and combination therapies that improve efficacy and patient compliance. It delves into how these innovations are enhancing treatment outcomes for conditions such as menopause, hypogonadism, thyroid disorders, and growth hormone deficiencies, providing safer and more personalized solutions.
Additionally, the report evaluates the competitive landscape, profiling major players in the global HRT market while spotlighting emerging technologies and novel therapeutic approaches expected to drive future growth. It provides an in-depth review of ongoing clinical developments, regulatory progress, and recent product approvals, making it a vital resource for understanding the rapidly advancing field of hormone replacement therapy.
Some of the key insights of the Hormone Replacement Therapy Market Report:
The hormone replacement therapy market is projected to expand at a CAGR of 6.48% from 2024 to 2030.
North America is estimated to hold a significant revenue share in the Hormone Replacement Therapy market.
In September 2024, the FDA's Oncologic Drugs Advisory Committee (ODAC) recognized the favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for the first-line treatment of locally advanced or metastatic ESCC and G/GEJ cancers with PD-L1 >1%.
In August 2024, the FDA approved Ascendis Pharma's Yorvipath (palopegteriparatide) as a parathyroid hormone replacement therapy for adults with hypoparathyroidism, with the first U.S. supply expected in early 2025.
In June 2024, Mangoceuticals announced the development of proprietary Oral Dissolvable Tablet (ODT) formulations of Enclomiphene Citrate, Pregnenolone, and DHEA to restore hormonal balance and naturally boost testosterone levels in men.
In May 2023, Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approval for VEOZAH (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.
In January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labor and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorders. This product was the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage.
Key players in the global Hormone Replacement Therapy market include Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F. Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.
Hormone Replacement Therapy Overview
Hormone Replacement Therapy (HRT) is a widely used treatment designed to replenish hormones that naturally decline due to aging or specific medical conditions. It is commonly prescribed for menopause-related symptoms in women, such as hot flashes, osteoporosis, and mood swings, as well as for hypogonadism and testosterone deficiency in men. Additionally, HRT plays a crucial role in managing conditions like hypothyroidism and growth hormone deficiencies. The therapy is available in various forms, including oral tablets, patches, injections, and topical gels, allowing personalized treatment approaches.
Advancements in hormone formulations, including bioidentical and plant-derived hormones, have improved safety and efficacy, addressing concerns related to long-term use. Increasing awareness of hormonal imbalances and their impact on overall health is driving demand for HRT, making it a significant segment in the global healthcare market.
Hormone Replacement Therapy Market Segment Analysis:
The Hormone Replacement Therapy market report offers market segment analysis for the forecast period 2024-2030, segmented into:
Hormone Replacement Therapy Market by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and Others)
Hormone Replacement Therapy Market by Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others)
Hormone Replacement Therapy Market by Route of Administration (Oral, Parenteral, and Transdermal)
Hormone Replacement Therapy Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World)
Download the Hormone Replacement Therapy Market Analysis report for key market trends, innovations, and growth drivers.
Hormone Replacement Therapy Market Dynamics
One of the key factors driving the growth of the hormone replacement therapy market is the increasing awareness among women about managing menopausal symptoms. As women age, estrogen and progesterone levels decline significantly, leading to hormonal imbalances. In response, the pituitary gland increases follicle-stimulating hormone (FSH) production, causing symptoms such as hot flashes, excessive sweating, and palpitations. With a growing global population of women reaching menopause, the demand for hormone replacement therapy to manage these symptoms is expected to rise.
Additionally, ongoing research and development efforts by key pharmaceutical companies are driving the discovery of novel treatments for hormonal imbalances. The increasing number of product approvals is further expanding the availability of hormone replacement therapies. Several companies are actively investing in the introduction of innovative therapies for conditions such as growth hormone deficiency and testosterone replacement, enhancing treatment options for both men and women.
However, certain challenges may hinder market growth. The high costs associated with drug development, potential side effects linked to long-term hormone therapy use, and stringent regulatory approval processes remain significant barriers. Despite these challenges, the overall hormone replacement therapy market is expected to expand steadily, driven by advancements in treatment options and increasing patient awareness.
North America Set to Lead the Growth of the Global Hormone Replacement Therapy Market
North America is expected to dominate the hormone replacement therapy market, driven by the increasing demand for hormone replacement drugs among women due to the rising prevalence of menopausal-related issues. Additionally, the growing incidence of growth deficiencies, thyroid disorders, osteoporosis, and hypogonadism, along with active research and development efforts, is fueling market expansion in the region.
The presence of key pharmaceutical companies, frequent product launches, and favorable reimbursement policies further support market growth. For instance, the increasing prevalence of thyroid-related conditions has led to a higher demand for hormone therapies, as these treatments play a crucial role in managing conditions like thyroid cancer and hormonal imbalances. Moreover, recent product relaunches and strategic collaborations among manufacturers are strengthening the market landscape.
With these factors in play, North America is expected to maintain its leadership in the hormone replacement therapy market throughout the forecast period.
Hormone Replacement Therapy Market Drivers
Growing awareness of menopause-related health issues and a rising aging population are increasing the demand for HRT to manage symptoms like osteoporosis, cardiovascular risks, and hormonal imbalances.
The development of safer, more effective hormone formulations, including bioidentical and plant-based options, has improved patient outcomes and increased adoption rates.
Hormone Replacement Therapy Market Barriers
Concerns about long-term HRT use, including increased risks of breast cancer, cardiovascular diseases, and stroke, limit patient adoption and regulatory approvals.
The cost of HRT, especially newer formulations and customized therapies, can be a financial burden for patients, with limited insurance reimbursement restricting accessibility.
To learn more about Hormone Replacement Therapy drivers and barriers, visit @ Hormone Replacement Therapy Competitive Landscape and Market Forecast Report
Table of Contents
1. Hormone Replacement Therapy Market Report Introduction
2. Hormone Replacement Therapy Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Hormone Replacement Therapy Market Key Factors Analysis
6. Hormone Replacement Therapy Market Porter's Five Forces Analysis
7. Hormone Replacement Therapy Market Layout
8. Hormone Replacement Therapy Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
15 minutes ago
- CTV News
As Musk's ‘robotaxi' rollout approaches, Democratic lawmakers in Texas try to throw up a roadblock
Elon Musk listens as President Donald Trump speaks during a news conference in the Oval Office of the White House, Friday, May 30, 2025, in Washington. (AP Photo/Evan Vucci) NEW YORK — A group of Democratic lawmakers in Texas is asking Elon Musk to delay the planned rollout of driverless 'robotaxis' in the state this weekend to assure that the vehicles are safe. In a letter, seven state legislators asked Tesla to wait until September when a new law takes effect that will require several checks before autonomous vehicles can be deployed without a human in the driver's seat. Tesla is slated to begin testing a dozen of what it calls robotaxis for paying customers on Sunday in a limited area of Austin, Texas. 'We are formally requesting that Tesla delay autonomous robotaxi operations until the new law takes effect on September 1, 2025,' the letter from Wednesday, June 18, reads. 'We believe this is in the best interest of both public safety and building public trust in Tesla's operations.' It's not clear if the letter will have much impact. Republicans have been a dominant majority in the Texas Legislature for more than 20 years. State lawmakers and Republican Gov. Greg Abbott have generally embraced Musk and the jobs and investment he has brought to Texas, from his SpaceX rocket program on the coast, to his Tesla factory in Austin. The company, which is headquartered in Austin, did not responded immediately to a request for comment from The Associated Press. The law will require companies to secure approval from the state motor vehicles department to operate autonomous cars with passengers. That approval, in turn, would depend on sufficient proof that the cars won't pose a high risk to others if the self-driving system breaks down, among other reassurances. Companies would also have to file detailed plans for how first responders should handle the cars if there is a problem, such as an accident. The letter asked Tesla to assure the legislators it has met all the requirements of the law even if it decides to go ahead with the test run this weekend. The letter was earlier reported by Reuters. Musk has made the robotaxi program a priority at Tesla and a failure would likely be highly damaging to the company's stock, which has already tumbled 20% this year. Musk's political views and his affiliation with the Trump administration have drastically reduced sales of Tesla, particularly in Europe, where Musk's endorsement of Germany's far-right Alternative for Germany party in February's election drew broad condemnation. Tesla shares bottomed out in March and have rebounded somewhat in recent months. Much of the rise reflects optimism that robotaxis will not only be deployed without a hitch, but that the service will quickly expand to other cities and eventually dominate the self-driving cab business. Rival Waymo is already picking up passengers in Austin and several other cities, and recently boasted of surpassing 10 million paid rides. In afternoon trading Friday, Tesla shares were largely unchanged at US$320. --- Bernard Condon, The Associated Press AP reporter Jim Vertuno contributed from Austin.
CTV News
24 minutes ago
- CTV News
Don't regulate us like radio, music streamer Spotify tells CRTC
A trading post sports the Spotify logo on the floor of the New York Stock Exchange on Tuesday, April 3, 2018. (AP Photo/Richard Drew, File) OTTAWA — Music streamer Spotify says Canada's federal broadcast regulator shouldn't impose rules meant for radio on streaming services. Appearing before a CRTC hearing today, company representatives compared regulating Spotify like a radio station to treating Uber like a horse and buggy. In its written submission, Spotify argued the CRTC doesn't have the jurisdiction to extend rules governing commercial negotiations and disputes in the broadcast sector to online players. The CRTC is holding a hearing on market dynamics as part of its work to implement the Online Streaming Act, which updated broadcasting laws to capture online platforms. During previous hearings, large cable and broadcasting companies like Bell and Rogers called on the CRTC to loosen existing rules for traditional players. They're taking aim at regulations governing how cable channels must be packaged and disputes about carriage of cable channels. This report by The Canadian Press was first published June 20, 2025 Anja Karadeglija, The Canadian Press
CBC
32 minutes ago
- CBC
VIA Rail and Unifor reach tentative agreement, avoiding a strike
Via Rail has reached a tentative deal with the union representing 2,400 of its workers across the country, the Crown corporation said on Friday. The deal averts a walkout involving members of Unifor, who had voted for a strike mandate to be exercised as early as Sunday. Unifor says the tentative agreement offers gains in wages, job security and working conditions. The union represents workers at VIA Rail stations, maintenance centres, the customer care centre, in administrative offices and on board trains. Unifor didn't release details of the deal, preferring to first inform its members at meetings scheduled over the coming weeks. VIA Rail has said it was committed to a fair and reasonable agreement while remaining competitive and providing quality service. The two parties had broken off contract talks earlier this month, setting the stage for a potential strike.
